Skip to main content
SpringerLink
Log in

Analisi dei costi in pazienti ad alto rischio di nefropatia indotta da mezzo di contrasto: i risultati per l’Italia dello studio NEPHRIC

Cost analysis in patients at high risk of contrast-induced nephropathy: Italian results of the NEPHRIC study

  • Published:
PharmacoEconomics Italian Research Articles

Summary

Objective

Contrast-induced nephropathy (CIN) is a clinically important and costly adverse event due to the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of two contrast media in patients at high risk of CIN.

Methods

The analysis was based on a randomized multinational clinical study comparing the nephrotoxic effects of an isosmolaR, non-ionic contrast medium, iodixanol, with those of a low-osmolar non-ionic contrast medium, iohexol. Resource utilization data were obtained from the study and from patients’ hospital records. Between-group differences in average costs were analyzed using a nonparametric bootstrap method.

Results

Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse events, of which six were acute renal failures, were noted in six patients receiving iohexol. Two patients in the iodixanol group had one non-serious reaction each. The mean hospitalisation cost per patient was € 871 lower after iodixanol than after iohexol. The mean per patient costs of treating adverse drug reactions were € 439 lower after iodixanol than after iohexol (p≤0.01). Iodixanol resulted cost-effective compared to iohexol.

Conclusions

The isosmolar contrast medium iodixanol appears to be cost-effective when compared to a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Sangiorgi G, Briguori C, Corvaja N, et al. Mezzi di contrasto e safety renale-cardiaca nel laboratorio di emodinamica. Emodinamica 2003; 34: 2–8

    Google Scholar 

  2. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years or older. Arch Intern Med 1995; 150: 1237–42

    Article  Google Scholar 

  3. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149–53

    Article  PubMed  CAS  Google Scholar 

  4. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416–20

    Article  PubMed  CAS  Google Scholar 

  5. Stevens MA, McCullogh PA, Tobin PJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE study (prevention of radiocontrast induced nephropathy clinical evaluation). J Am Coll Cardiol 1999; 33: 403–11

    Article  PubMed  CAS  Google Scholar 

  6. Porter GA. Contrast-associated nephropathy: presentation, pathophysiology, and management. Miner Electrolyte Metab 1994; 20: 232–43

    PubMed  CAS  Google Scholar 

  7. Scanlon PJ, Faxon DP, Audet AM, et al. The ACC/AHA guidelines for coronary angiography: a report of the ACC/AHA task force on practice guidelines (Committee on Coronary Angiography). J Am Coll Cardiol 1999; 33: 1756–824

    Article  PubMed  CAS  Google Scholar 

  8. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–64

    Article  PubMed  Google Scholar 

  9. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9: 1602–13

    Article  PubMed  CAS  Google Scholar 

  10. Barrett BJ, Carlise EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171–8

    PubMed  CAS  Google Scholar 

  11. Rudnik MK, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254–61

    Article  Google Scholar 

  12. Barret BJ, Parfrey PS, Foley RN, et al. An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization. Med Decis Making 1994; 14: 325–35

    Article  Google Scholar 

  13. Steinberg EP, Moore RD, Powe NR, et al. Safety and cost-effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography. N Engl J Med 1992; 326: 425–30

    Article  PubMed  CAS  Google Scholar 

  14. Klow NE, Levorstad K, Berg KJ, et al. Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects. Acta Radiol 1993; 34: 72–7

    PubMed  CAS  Google Scholar 

  15. Calvo MV, Pilar del Val M, Mar Alvarez M, et al. Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography. Am J Hosp Pharm 1992; 49: 577–84

    PubMed  CAS  Google Scholar 

  16. Singh K, Sundgren R, Bolstad B, et al. Iodixanol in abdominal digital subtraction angiography. A randomized, double-blind, parallel trial with iodixanol and iohexol. Acta Radiol 1993; 34: 242–5

    Article  PubMed  CAS  Google Scholar 

  17. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491–9

    Article  PubMed  CAS  Google Scholar 

  18. Danchin N, Macaya C, Tao WY. Economic analysis of the use of contrast media during percutaneous coronary intervention (PCI) in France and Spain. Value Health 2003; 6: 659–63

    Article  Google Scholar 

  19. Fischbach R, Landwehr P, Lackner K, et al. Iodixanol vs. iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Eur Radiol 1996; 6: 9–13.

    Article  PubMed  CAS  Google Scholar 

  20. Hill JA, Cohen MB, Kou WH, et al. Iodixanol, a new iso-osmotic contrast agent compared with iohexol in cardiac angiography. Am J Cardiol 1994; 74: 57–63

    Article  PubMed  CAS  Google Scholar 

  21. Thorstensen O, Albrechtsson U, Calissendorff B, et al. Iodixanol in femoral arteriography. A randomized, double-blind, phase III, parallel study with iodixanol 270 mg I/ml and iohexol 300 mg I/ml. Acta Radiol 1994; 35: 629–31

    PubMed  CAS  Google Scholar 

  22. Regione Lombardia. Tariffario delle prestazioni specialistiche e ambulatoriali della Regione Lombardia, gennaio 2004. www.regione.lombardia.it

  23. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3: 1–134

    PubMed  CAS  Google Scholar 

  24. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1987

    Google Scholar 

  25. Efron B, Tibshirani R. An Introduction to the Bootstrap. Boca Raton, FL: CRC Press, 1998

    Google Scholar 

  26. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41: 1274–9

    Article  PubMed  CAS  Google Scholar 

  27. Taliercio CP, Vliestra RE, Ilstrup DM, et al. A randomized comparison of nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991; 17: 384–90

    Article  PubMed  CAS  Google Scholar 

  28. Dimick JB, Pronovost PJ, Cowan JA, et al. Complications and costs after high-risk surgery: where should we focus quality improvement initiatives? J Am Coll Surg 2003; 196: 671–8

    Article  PubMed  Google Scholar 

  29. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring hemodialysis after percutaneous coronary intervention. Catheter Cardiovasc Interv 2001; 52(4): 417–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S.A.V.E - Studi Analisi Valutazioni Economiche, Via Previati 74, 20149, Milano, Italia

    G. L. Colombo & G. Serra

  2. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

    J. Lundkvist

  3. Azienda Ospedaliera di Busto Arsizio, Varese, Italia

    M. Caruggi

  4. Università Cattolica del Sacro Cuore, Milano, Italia

    M. Vinci

Authors
  1. G. L. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Lundkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Caruggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Serra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Vinci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. L. Colombo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colombo, G.L., Lundkvist, J., Caruggi, M. et al. Analisi dei costi in pazienti ad alto rischio di nefropatia indotta da mezzo di contrasto: i risultati per l’Italia dello studio NEPHRIC. Pharmacoeconomics-Ital-Res-Articles 7, 145–154 (2005). https://doi.org/10.1007/BF03320544

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320544

Search

Navigation